{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.74","upperLimit":"15.30","value":"3.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"description":"The probability of complete clinical response (i.e. proportion of participants) (assessed using GOG RECIST criteria) of paclitaxel as second line chemotherapy in measurable disease patients with malignant tumors of the ovarian stroma","dispersionType":"80% Confidence Interval","groups":[{"description":"Patients receive paclitaxel IV over 3 hours on day 1. Treatment continues every 21 days in the absence of disease progression or unacceptable toxicity.\n\nPaclitaxel: Given IV","id":"OG000","title":"Treatment (Paclitaxel)"}],"paramType":"NUMBER","populationDescription":"Eligible and evaluable","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Probability of Complete Clinical Response","type":"PRIMARY","unitOfMeasure":"Percentage of Participants"}